{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:31:10Z","timestamp":1793766670696,"version":"4.6.1"},"reference-count":362,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.critrevonc.2020.103038","type":"journal-article","created":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T11:15:42Z","timestamp":1593861342000},"page":"103038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Mantle cell lymphoma"],"prefix":"10.1016","volume":"153","author":[{"given":"Sergio","family":"Cortelazzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurilio","family":"Ponzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s J.M.","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2020.103038_bib0005","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a nordic lymphoma group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0010","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a nordic lymphoma group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0015","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a nordic lymphoma group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0020","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/annonc\/mdx333","article-title":"Observation as the initial management strategy in patients with mantle cell lymphoma","volume":"28","author":"Abrisquette","year":"2017","journal-title":"Ann. Oncol."},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2020.103038_bib0025","article-title":"Lenalidomide-rituximab bendamustine in first line for patients >65 with mantle cell lymphoma: final results of the nordic lymphoma group MCL4 (LENA-BERIT) phase I\/II trial","volume":"33","author":"Albertsson-Lindblad","year":"2015","journal-title":"Hematol. Oncol. (ICML abstracts)."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0030","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.24086","article-title":"Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the national cancer data Base from 1998 to 2011","volume":"90","author":"Al-Hamadani","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0035","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.3317825","article-title":"Development of the primary antibody repertoire","volume":"238","author":"Alt","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0040","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/cncr.27898","article-title":"Using primary site as a predictor of survival in mantle cell lymphoma","volume":"119","author":"Ambinder","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0045","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood.V90.10.4212","article-title":"Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease","volume":"90","author":"Andersen","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0050","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0301-472X(02)00807-X","article-title":"Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1\/JH rearrangements in mantle cell lymphoma","volume":"30","author":"Andersen","year":"2002","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0055","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0060","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central cancer treatment group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0065","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a multi-center phase 2 study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0070","first-page":"18","article-title":"Non-Hodgkin\u2019s lymphoproliferative disorders involving the spleen","volume":"10","author":"Arber","year":"1997","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0075","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2013.088377","volume":"98","author":"Arranz","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0080","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3109\/10428194.2012.760041","article-title":"An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA","volume":"54","author":"Aschebrook-Kilfoy","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0085","first-page":"3123","article-title":"Matched unrelated donor stem cell transplantation for relapsed or refractory mantle cell lymphoma.A retrospective analysis from the EBMT lymphoma working party","volume":"108","author":"Avivi","year":"2006","journal-title":"ASH Annual Meet Abstr."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0090","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2017-04-776740","article-title":"Sox 11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma","volume":"130","author":"Balsas","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103038_bib0095","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00000478-199207000-00001","article-title":"Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data","volume":"16","author":"Banks","year":"1992","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(00)00255-2","article-title":"Mantle-cell lymphoma","volume":"2","author":"Barista","year":"2001","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0105","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2141.2005.05777.x","article-title":"Activity and safety of combined rituximab with chlorambucil in patients with mantle celllymphoma","volume":"131","author":"Bauwens","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0110","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"PNAS"},{"issue":"February","key":"10.1016\/j.critrevonc.2020.103038_bib0115","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3109\/10428194.2011.608445","article-title":"A phase I study evaluating ibritumomab tiuxetan (zevalin\u00ae) in combination with bortezomib (velcade\u00ae) in relapsed\/refractory mantle cell and low grade B-cell non-hodgkin lymphoma","volume":"53","author":"Beaven","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0120","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/s12859-017-1923-2","article-title":"HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data","volume":"18","author":"Beccuti","year":"2017","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0125","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdl316","article-title":"A phase II study of bortezomib in mantle cell lymphoma: the national cancer institute of Canada clinical trials group trial IND.150","volume":"18","author":"Belch","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0130","doi-asserted-by":"crossref","first-page":"12461","DOI":"10.1073\/pnas.1018941108","article-title":"A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma","volume":"108","author":"Beltrana","year":"2011","journal-title":"PNAS"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0135","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/10428194.2012.711828","article-title":"Limited-stage mantle cell lymphoma: treatment outcomes at the princess Margaret Hospital","volume":"54","author":"Bernard","year":"2013","journal-title":"Leuk Lymphoma."},{"issue":"14","key":"10.1016\/j.critrevonc.2020.103038_bib0140","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2015-05-647834","article-title":"Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse","volume":"126","author":"Bernard","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0145","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","article-title":"A phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213","volume":"24","author":"Bernstein","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0150","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.biocel.2007.04.026","article-title":"The cellular origin of mantle cell lymphoma","volume":"39","author":"Bertoni","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0155","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/10428199909167400","article-title":"Clonality assessment in blood of patients with mantle cell lymphoma","volume":"32","author":"Bertoni","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"Abstract","key":"10.1016\/j.critrevonc.2020.103038_bib0160","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood.V126.23.335.335","article-title":"Predictive power of FDG-PET parameters at diagnosis and after induction in patients with mantle cell lymphoma, interim results from the LyMa-PET project, conducted on behalf of the Lysa group","volume":"126","author":"Bodet-Milin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0165","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","article-title":"Mantle cell lymphoma:presenting features, response to therapy, and prognostic factors","volume":"82","author":"Bosch","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0170","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3324\/haematol.11267","article-title":"Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations","volume":"93","author":"Bottcher","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0175","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3324\/haematol.11267","article-title":"Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations","volume":"93","author":"B\u00f6ttcher","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0180","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/10428190802216707","article-title":"Positron emission tomography in mantle cell lymphoma","volume":"49","author":"Brepoels","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0185","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","article-title":"Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicentre phase II study","volume":"15","author":"Brugger","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0190","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2010.33.7055","article-title":"Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation","volume":"29","author":"Budde","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0195","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clml.2016.01.001","article-title":"Differences in quality of life between bendamustine-rituximab and R-CHOP\/R-CVP in patients with previously untreated advanced indolent Non-Hodgkin lymphoma or mantle cell lymphoma","volume":"16","author":"Burke","year":"2016","journal-title":"Clinical Lymphoma, Myeloma & Leukemia."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0200","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood.V126.23.338.338","volume":"126","author":"Callanan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0205","first-page":"993","article-title":"Retrospective analysis of mantle cell lymphoma: experience of the \u201cGruppo Italiano per lo Studio dei Linfomi\u201d (GISL)","volume":"83","author":"Callea","year":"1998","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0210","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V99.1.238","article-title":"ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances","volume":"99","author":"Camacho","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0215","first-page":"1860","article-title":"Report of the Committee on Hodgkin\u2019s Disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0220","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3324\/haematol.2011.052621","article-title":"In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior","volume":"97","author":"Carvajal-Cuenca","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0225","first-page":"260","article-title":"Gastrointestinal lymphomas: an overview with emphasis on new findings and diagnostic problems","volume":"13","author":"Chan","year":"1996","journal-title":"Semin. Diagn. Pathol."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103038_bib0230","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3109\/10428194.2012.656628","article-title":"Survival trends in mantle cell lymphoma in the United States over sixteen years 1992\u20132007","volume":"53","author":"Chandran","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0235","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2141.2011.08820.x","article-title":"VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: A Wisconsin Oncology Network study","volume":"155","author":"Chang","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0240","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood.V128.22.149.149","article-title":"Durable remissions with the VcR-CVAD regimen for mantle cell lymphoma (MCL), regardless of age: Long-term follow-up of a Wisconsin Oncology Network (WON) study","volume":"128","author":"Chang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0245","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.anndiagpath.2014.03.006","article-title":"Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and\/or 13q14","volume":"18","author":"Chapman-Fredricks","year":"2014","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0250","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.anndiagpath.2014.03.006","article-title":"Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and\/or 13q14","volume":"18","author":"Chapman-Fredricks","year":"2014","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0255","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0260","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdt139","article-title":"Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network","volume":"24","author":"Cheah","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0265","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0270","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2008-03-142182","article-title":"Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma","volume":"112","author":"Chen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0275","volume":"126","author":"Chen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0280","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","article-title":"Bendamustine: rebirth of an old drug","volume":"27","author":"Cheson","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0285","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0290","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.2735.2735","article-title":"The combination of weekly infusion of rituximab and bortezomib is effective in relapsed or refractory indolent and mantle cell lymphoma: long-term results of phase II BRIL06 study of the Fondazione Italiana Linfomi (FIL)","volume":"126","author":"Chiappella","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0295","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdv074","article-title":"Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL)","volume":"26","author":"Chihara","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0300","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/bjh.13486","article-title":"Prognostic model for mantle cell lymphoma in the rituximab era: a nation wide study in Japan","volume":"170","author":"Chihara","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0305","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.13796","article-title":"Rituximab plus hyper-CVAD alternating with MTX\/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center","volume":"172","author":"Chihara","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0310","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1365-2141.1998.00684.x","article-title":"Bone marrow and peripheral blood involvement in mantle cell lymphoma","volume":"101","author":"Cohen","year":"1998","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0315","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/bmt.2013.46","article-title":"Association of pre-transplantation positron emission tomography\/computed tomography and outcome in mantle cell lymphoma","volume":"48","author":"Cohen","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0320","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/cncr.30068","article-title":"Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma","volume":"122","author":"Cohen","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0325","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","article-title":"Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation","volume":"16","author":"Cook","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0330","first-page":"1282","article-title":"Update of a GITIL cohort study: frontline high dose sequential chemotherapy with rituximab and autologous stem cell transplantation induces a high rate of long term remissions in patients with mantle cell lymphoma","volume":"110","author":"Cortelazzo","year":"2007","journal-title":"ASH Annual Meet Abstr"},{"issue":"s1","key":"10.1016\/j.critrevonc.2020.103038_bib0335","first-page":"3","article-title":"High dose sequential chemotherapy with rituximab and ASCT as first line therapy in adult MCL patients: clinical and molecular response of the MCL0208 trial, a FIL study","volume":"100","author":"Cortelazzo","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0340","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19092475","article-title":"Long Non-coding RNAs Guide the fine-tuning of Gene regulation in B-cell development and malignancy","volume":"19","author":"Dahl","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0345","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct functional significance of akt and mTOR constitutive activation in mantle cell lymphoma","volume":"111","author":"Dal Col","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0350","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory Non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Cin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0355","first-page":"425","article-title":"Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma","volume":"91","author":"de Guibert","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0360","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/jcp.42.9.962","article-title":"Leukaemic phase of mantle zone (intermediate) lymphoma: its characterisation in 11 cases","volume":"42","author":"De Oliveira","year":"1989","journal-title":"J. Clin. Pathol."},{"issue":"Abstract","key":"10.1016\/j.critrevonc.2020.103038_bib0365","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood.V112.11.581.581","article-title":"RCHOP and RDHAP followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): final results of a phase II study from the GELA","volume":"112","author":"Delarue","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0370","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0375","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","article-title":"Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group","volume":"111","author":"Determann","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0380","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/leu.2010.91","article-title":"Mantle cell lymphoma: transcriptional regulation by microRNAs","volume":"24","author":"Di Lisio","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0385","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2009.008474","article-title":"Strong lymphoid nuclear expressionof SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt\u2019s lymphoma","volume":"94","author":"Dictor","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0390","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/annonc\/mdu097","article-title":"Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"25","author":"Dietrich","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0395","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jmoldx.2015.05.007","article-title":"Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR","volume":"17","author":"Drandi","year":"2015","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0400","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.bbmt.2007.10.019","article-title":"Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma","volume":"14","author":"Dreger","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0405","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3324\/haematol.2015.127472","article-title":"On behalf of the European mantle cell lymphoma network. Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience","volume":"100","author":"Dreyling","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0410","first-page":"4608","article-title":"Alterations of the cyclin D1\/p16-pRB pathway in mantle cell lymphoma","volume":"57","author":"Dreyling","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0415","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"Abstract","key":"10.1016\/j.critrevonc.2020.103038_bib0420","first-page":"300","article-title":"European Mantle Cell Lymphoma Network: an update on current first line trials","volume":"19","author":"Dreyling","year":"2008","journal-title":"Ann Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0425","first-page":"769","article-title":"Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission in mantle cell lymphoma:Long term follow up of a randomized trial of the European","volume":"112","author":"Dreyling","year":"2008","journal-title":"MCL Network. ASH Annual Meet. Abstr."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0430","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann. Oncol."},{"issue":"Supplement 3","key":"10.1016\/j.critrevonc.2020.103038_bib0435","doi-asserted-by":"crossref","first-page":"iii83","DOI":"10.1093\/annonc\/mdu264","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Dreyling","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0440","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0445","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/1097-0142(19900801)66:3<522::AID-CNCR2820660320>3.0.CO;2-4","article-title":"Mantle zone lymphoma. A clinicopathologic study of 22 cases","volume":"66","author":"Duggan","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0450","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1182\/blood.V120.21.3672.3672","article-title":"Bortezomib plus DA-EPOCH-R induction therapy followed by maintenance bortezomib versus observation in newly diagnosed mantle cell lymphoma","volume":"120","author":"Dunleavy","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0455","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2141.2007.06908.x","article-title":"A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma","volume":"140","author":"Evens","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"Abstract","key":"10.1016\/j.critrevonc.2020.103038_bib0460","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.V110.11.387.387","article-title":"A multi center trial of hyperCVAD+Rituxan in patients with newly diagnosed mantle cell lymphoma","volume":"110","author":"Epner","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0465","article-title":"A phase II multicenter study of the histone deacetylase inhibitor abexinostat in relapsed\/ refractory follicular lymphoma and mantle cell lymphoma[abstract]","volume":"120","author":"Evens","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2020.103038_bib0470","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.3816\/CLM.2007.s.034","article-title":"Update of the M. D.Anderson cancer center experience with hyper-CVAD and rituximab for the treatment of mantle cell and burkitt-type lymphomas","volume":"8","author":"Fayad","year":"2007","journal-title":"Clin. Lymphoma Myeloma"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0475","article-title":"Outcome of patients with mantle cell lymphoma undergoing autologous versus reduced intensity allogeneic transplantation","volume":"22","author":"Fenske","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0480","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality","volume":"32","author":"Fenske","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0485","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1002\/cncr.29502","article-title":"A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: a Wisconsin Oncology Network study","volume":"121","author":"Fenske","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0490","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fernandez","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0495","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/annonc\/mdm447","article-title":"Central nervous system involvementin mantle cell lymphoma","volume":"19","author":"Ferrer","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0500","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00277-013-1797-y","article-title":"Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma","volume":"92","author":"Ferrero","year":"2013","journal-title":"Ann. Haematol."},{"issue":"Suppl. 6","key":"10.1016\/j.critrevonc.2020.103038_bib0505","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/annonc\/7.suppl_6.S35","article-title":"Mantle-cell lymphoma: classification and therapeutic implications","volume":"7","author":"Fisher","year":"1996","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0510","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0515","first-page":"2748","article-title":"Rituximab, lenalidomide, and bortezomib in the first-line or second-line treatment of patients with mantle cell lymphoma a phase I\/II trial","volume":"120","author":"Flinn","year":"2012","journal-title":"ASH Annual Meeting Abstracts."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0520","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0525","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0530","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0535","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","article-title":"High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence or long-term remission","volume":"16","author":"Freedman","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0540","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","article-title":"The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma","volume":"117","author":"Friedberg","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0545","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2005-04-1753","article-title":"Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling","volume":"106","author":"Fu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0550","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2005-04-1753","article-title":"Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling","volume":"106","author":"Fu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0555","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/bjh.12769","article-title":"Ofatumumab monotherapy in relapsed\/refractory mantle cell lymphoma \u2013 a phase II trial","volume":"165","author":"Furtado","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0560","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1309\/AJCPV8LN5ENMZOVY","article-title":"Immunophenotypic variations in mantle cell lymphoma","volume":"132","author":"Gao","year":"2009","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0565","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00277-014-2077-1","article-title":"Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience","volume":"93","author":"Garc\u00eda-Noblejas","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0570","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2040620710396752","article-title":"Long-term results of fludarabine\/melphalan as a reduced-intensity conditioning regimen in mantle cell lymphoma: the GELTAMO experience","volume":"2","author":"Gayoso","year":"2011","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0575","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Nordic lymphoma group. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a non randomized phase 2 multicenter study by the nordic lymphoma group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0580","first-page":"352","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC +autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0585","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.12683","article-title":"Prognostic impact of monocyte count at presentation in mantle cell lymphoma","volume":"164","author":"George","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0590","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2006-01-0015","article-title":"A chromosomal translocation in cyclin D1-negative\/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus","volume":"108","author":"Gesk","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0595","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0600","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0605","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3816\/CLM.2008.n.019","article-title":"[18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma","volume":"8","author":"Gill","year":"2008","journal-title":"Clin. Lymphoma Myeloma."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0610","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2141.2009.07835.x","article-title":"Mantle cell lymphoma with central nervous system involvement: frequency and clinical features","volume":"147","author":"Gill","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0615","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ijrobp.2015.07.2265","article-title":"Management trends and outcomes for stage I to II mantle cell lymphoma using the national cancer data Base: ascertaining the ideal treatment paradigm","volume":"93","author":"Gill","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0620","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemoradioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0625","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2012.45.3050","article-title":"MicroRNA signature obtained from the comparison of aggressive with indolent Non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma","volume":"31","author":"Goswami","year":"2013","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0630","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0635","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0640","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.3109\/10428194.2014.907891","article-title":"A phase I\/II study of the pan bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma","volume":"55","author":"Goy","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0645","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","article-title":"p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis","volume":"87","author":"Greiner","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0650","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"PNAS"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0655","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/10428190500052461","article-title":"Autografting followed by rituximab for chemosensitive mantle cell lymphoma: a pilot study and literature review","volume":"46","author":"Grigg","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0660","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ncponc0297","article-title":"Is rituximab effective as a single agent in mantle-celllymphoma?","volume":"2","author":"Grillo-Lopez","year":"2005","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0665","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/PAI.0b013e3181bb9edf","article-title":"BCL6, MUM1,and CD10 expression in mantle cell lymphoma","volume":"18","author":"Gualco","year":"2010","journal-title":"Appl. Immunohistochem Mol. Morphol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0670","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0675","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2011-03-343434","article-title":"Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases","volume":"118","author":"Hadzidimitriou","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0680","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2011.162","article-title":"Impact of TP53 mutation and 17p deletion in mantle cell lymphoma","volume":"25","author":"Halldorsdottir","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0685","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/gcc.20836","article-title":"High-resolution genomic screening in mantle cell lymphoma-specific changes correlate with genomic complexity, the proliferation signature and survival","volume":"50","author":"Halld\u00f3rsd\u00f3ttir","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0690","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","article-title":"Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for International Blood and Marrow Transplant Research","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0695","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0700","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1158\/0008-5472.CAN-04-1526","article-title":"CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a\/ARF locus","volume":"65","author":"Hernandez","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0705","first-page":"12","article-title":"Immunochemotherapy (RMCP) in advanced mantle cell lymphoma is not superior to chemotherapy(MCP) alone. 50 months up date of the OSHO phase III study (OSHO#39)","volume":"19","author":"Herold","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0710","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0715","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103038_bib0720","first-page":"1","article-title":"Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis","volume":"4","author":"Hess","year":"2015","journal-title":"Experi. Hematol.Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0725","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2015.60","article-title":"Safety and efficacy of temsirolimus in combination with bendamustine and rituximab in relapsed mantle cell and follicular lymphoma","author":"Hess","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0730","first-page":"3051","article-title":"Autologous stem-cell transplant with a rituximab purge and maintenance vs. standard chemotherapy for mantle cell lymphoma: extended follow-up of a matched pair analysis","volume":"108","author":"Hicks","year":"2006","journal-title":"ASH Annual Meet Abstr."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0735","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1158\/1078-0432.CCR-10-2876","article-title":"Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms","volume":"17","author":"Holkova","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0740","first-page":"712","article-title":"Small lymphocytic lymphomas with predominant splenomegaly: a comparison of immunophenotypes with cases of predominant lymphadenopathy","volume":"4","author":"Hollema","year":"1991","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0745","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ajh.22126","article-title":"Utility of positron emission tomography scans in mantle cell lymphoma","volume":"86","author":"Hosein","year":"2011","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0750","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0755","first-page":"3049","article-title":"The addition of rituximab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma: long term results of a randomized GLSG trial","volume":"112","author":"Hoster","year":"2008","journal-title":"ASH Annual Meet Abstr"},{"issue":"October (S4)","key":"10.1016\/j.critrevonc.2020.103038_bib0760","volume":"32","author":"Hoster","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0765","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0770","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/annonc\/mdr450","article-title":"French GOELAMS group. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS","volume":"23","author":"Houot","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0775","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0780","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3892\/mco.2016.792","article-title":"Cutaneous involvement as a rare first sign of systemic mantle cell lymphoma: a case report and review of the literature","volume":"4","author":"Hrgovici","year":"2016","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0785","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2559.2012.04260.x","article-title":"SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma","volume":"61","author":"Hsiao","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0790","first-page":"1042","article-title":"Mantle cell lymphoma with in situ or mantle zone growth pattern: a study of five cases and review of literature","volume":"7","author":"Hsu","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0795","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1182\/blood-2014-06-584193","article-title":"miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator","volume":"125","author":"Husby","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0800","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/2040620711412418","article-title":"Initial therapy of mantle cell lymphoma","volume":"2","author":"Inwards","year":"2011","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0805","first-page":"2746","article-title":"Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantle cell lymphoma (MCL) (N0189)","volume":"108","author":"Inwards","year":"2006","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0810","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.23537","article-title":"Long-term results of the treatment of patients with mantle cell lymphoma with cladribine(2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in theNorth Central cancer treatment group","volume":"113","author":"Inwards","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0815","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/annonc\/mdu273","article-title":"Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma","volume":"10","author":"Inwards","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0820","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1182\/blood-2011-07-370122","article-title":"Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis","volume":"119","author":"Iqbal","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0825","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.15411","article-title":"Four year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"18","author":"Jain","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0830","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Jares","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0835","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm phase 2 trial","volume":"53","author":"Jekerman","year":"2018","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0840","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/annonc\/mdh093","article-title":"Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B cell lymphomas: results of a phase II study","volume":"15","author":"Jermann","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0845","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1182\/blood-2010-05-285403","article-title":"Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs","volume":"116","author":"Jima","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0850","first-page":"2747","article-title":"90Y-zevalin(R) (90YIbritumomabTiuxetan) radioimmunotherapy (RIT) consolidation of FCM induction chemotherapy in mantle cell lymphoma (MCL) patients: results from the PLRG upon completed enrollment","volume":"108","author":"Jurczak","year":"2006","journal-title":"ASH Annual Meet Abstr."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0855","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","article-title":"Maintenance rituximab following induction chemoimmunotherapy may prolong progression free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network","volume":"17","author":"Kahl","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0860","first-page":"265","article-title":"VcR-CVAD produces a high complete response rate in untreated mantle cell lymphoma: a phase IIstudy from the Wisconsin oncology network","volume":"112","author":"Kahl","year":"2008","journal-title":"ASHAnnual Meet Abstr."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0865","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3K delta inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0870","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.bmt.1701941","article-title":"Randomized trial of peripheral blood progenitor cell vs. bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin\u2019s lymphoma and Hodgkin\u2019s disease: a clinical and molecular analysis","volume":"24","author":"Kanteti","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0875","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/leu.2012.334","article-title":"Lymphoma \u2018type k\u2019 in memory of Karl Lennert","volume":"27","author":"Kappler","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0880","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbmt.2004.09.007","article-title":"Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma","volume":"11","author":"Kasamon","year":"2005","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0885","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","article-title":"The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma","volume":"107","author":"Katzenberger","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103038_bib0890","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.3109\/10428194.2014.882506","article-title":"Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography\/computed tomography in mantle cell lymphoma?","volume":"55","author":"Kedmi","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0895","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.3109\/10428194.2014.882506","article-title":"Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography\/computed tomography in mantle cell lymphoma?","volume":"55","author":"Kedmi","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0900","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3109\/10428194.2011.580404","article-title":"Maintenance rituximab following induction chemoimmunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network","volume":"52","author":"Kenkrei","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0905","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0910","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1023\/A:1008380527502","article-title":"Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy","volume":"10","author":"Khouri","year":"1999","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0915","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/cncr.11838","article-title":"Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score","volume":"98","author":"Khouri","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0920","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","article-title":"Nonablative allogeneic stem cell transplantation for advanced\/recurrent mantle-cell lymphoma","volume":"21","author":"Khouri","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0925","doi-asserted-by":"crossref","first-page":"871","DOI":"10.5858\/arpa.2012-0197-CR","article-title":"Transformation of indolent mantle cell lymphoma to pleomorphic mantle cell lymphoma","volume":"136","author":"Kiel","year":"2012","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0930","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2003-05-1383","article-title":"VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome","volume":"102","author":"Kienle","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0935","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1200\/JCO.2006.08.7999","article-title":"Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors","volume":"25","author":"Kienle","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0940","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/j.1349-7006.2011.01988.x","article-title":"Small cell variant of mantle cell lymphoma is an indolent lymphoma characterized by bone marrow involvement, splenomegaly, and a low Ki-67 index","volume":"102","author":"Kimura","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0945","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0950","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.13234","article-title":"Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study","volume":"168","author":"Kirschey","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0955","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0960","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/hon.2106","article-title":"Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour-associated macrophages","volume":"32","author":"Koh","year":"2014","journal-title":"Hematol. Oncol."},{"issue":"123","key":"10.1016\/j.critrevonc.2020.103038_bib0965","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood-2013-12-541953","article-title":"Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM\/C in non-CR patients before transplant in mantle cell lymphoma","volume":"8","author":"Kolstad","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0970","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/JCO.2003.09.057","article-title":"Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada clinical trials group","volume":"21","author":"Kouroukis","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0975","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3109\/10428194.2010.546015","article-title":"A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada clinical trials group (IND 172)","volume":"52","author":"Kouroukis","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0980","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib0985","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2007.11.9248","article-title":"Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high dose chemotherapy in patients with non-Hodgkin\u2019s lymphoma","volume":"26","author":"Krishnan","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0990","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00277-014-2087-z","article-title":"Allogeneic stem cell transplantation for mantle cell lymphoma-final report from the prospective trials of the East German Study Group Haematology\/Oncology (OSHO)","volume":"93","author":"Kr\u00fcger","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib0995","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/ajcp\/105.6.737","article-title":"bc1-1 rearrangement and cyclin D1 protein expression in multiple lymphomatous polyposis","volume":"105","author":"Kumar","year":"1996","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1000","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1005","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"issue":"Abstract","key":"10.1016\/j.critrevonc.2020.103038_bib1010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2018-99-110289","article-title":"Lenalidomide maintenance after autologous transplantation prolongs PFS in young MCL patients: results of the randomized phase III MCL0208 trial from fondazione italiana linfomi (FIL)","volume":"132","author":"Ladetto","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1015","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3324\/haematol.2011.041392","article-title":"Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma","volume":"96","author":"Lamm","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1020","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00432-013-1475-4","article-title":"Rituximab, Ara-C, dexamethasone and oxaliplatin (R-ADOx) is effective for treatment of elderly patients with relapsed mantle cell lymphoma","volume":"139","author":"Lamm","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1025","first-page":"2093","article-title":"Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis form the NCCN NHL database","volume":"119","author":"Le Case","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1030","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab maintenance after autologous stem cell transplantation in mantle cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1035","doi-asserted-by":"crossref","DOI":"10.1002\/hon.2438_73","article-title":"Obinutuzumab plus ibrutinib in Relapse\/Refractory mantle cell lymphoma patients: first results of the Oasis phase I trial","author":"Le Gouill","year":"2017","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1040","first-page":"1275","article-title":"Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study","volume":"89","author":"Lefrere","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1045","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/annonc\/mdg414","article-title":"Limited-stage mantle cell lymphoma","volume":"14","author":"Leitch","year":"2003","journal-title":"Ann. Onco."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1050","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/cncr.20483","article-title":"The role of fludarabine in the treatment of follicular and mantle cell lymphoma","volume":"101","author":"Lenz","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1055","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00277-014-2049-5","article-title":"Mantle cell lymphoma epidemiology: a population-based study in France","volume":"93","author":"Leux","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1060","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3324\/haematol.2011.050203","article-title":"Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909","volume":"97","author":"Liu","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1065","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","article-title":"A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma","volume":"125","author":"Maddocks","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1070","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","article-title":"Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion","volume":"96","author":"Magni","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1075","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/bmt.2008.349","article-title":"High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen","volume":"43","author":"Magni","year":"2009","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1080","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1182\/blood.V118.21.1647.1647","article-title":"Safety, tolerability and activity of ofatumumab, bendamustine and dexamethasone combination as first-line treatment of mantle-cell lymphoma in the elderly: a multicenter study","volume":"118","author":"Magni","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1085","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/annonc\/mdh069","article-title":"Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis","volume":"15","author":"Mangel","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1090","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1095","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1100","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1105","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/blood.V128.22.150.150","article-title":"A phase I trial of ibrutinib plus palbociclib in patients with previously treated mantle cell lymphoma","volume":"128","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1110","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1002\/cncr.26731","article-title":"Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD","volume":"118","author":"Mato","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1115","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1080\/10428190410001723331","article-title":"The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients","volume":"45","author":"Matutes","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1120","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjh.12046","article-title":"Guidelines for the investigation and management of mantle cell lymphoma","volume":"159","author":"McKay","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1125","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2013-01-478834","article-title":"The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma","volume":"121","author":"Meissner","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1130","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","article-title":"Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from gruppo italiano studio linfomi","volume":"156","author":"Merli","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1135","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hon.2900070505","article-title":"Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis","volume":"7","author":"Meusers","year":"1989","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1140","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1200\/jco.2004.22.90140.6697","article-title":"Results of a pilot trial of fludarabine, mitoxantrone and rituximab in mantle cell lymphoma","volume":"22","author":"Mohrbacher","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1145","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1200\/JCO.1996.14.3.941","article-title":"CNS involvement in mantle-cell lymphoma","volume":"14","author":"Montserrat","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1150","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3109\/10428194.2014.938333","article-title":"Therapy with bortezomib plus lenalidomide for relapsed\/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501)","volume":"56","author":"Morrison","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1155","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3109\/10428194.2014.938333","article-title":"Therapy with bortezomib plus lenalidomide for relapsed\/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501)","volume":"56","author":"Morrison","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1160","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdl395","article-title":"Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma","volume":"18","author":"Morschhauser","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1165","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","article-title":"Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1170","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/00000478-199604000-00007","article-title":"Lymphomatous polyposis. A neoplasm of either follicular mantle or germinal center cell origin","volume":"20","author":"Moynihan","year":"1996","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1175","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/00000478-199604000-00007","article-title":"Lymphomatous polyposis. A neoplasm of either follicular mantle or germinal center cell origin","volume":"20","author":"Moynihan","year":"1996","journal-title":"Am. J. Surg. Pathol."},{"issue":"Suppl:S90-5","key":"10.1016\/j.critrevonc.2020.103038_bib1180","article-title":"Effect of radiotherapy on the survival of patients with stage I and stage II mantle cell lymphoma: analysis of the surveillance, epidemiology and end results database","volume":"14","author":"Murthy","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1185","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/bmt.2015.156","article-title":"Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era","volume":"50","author":"Mussetti","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1190","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/ajcp\/68.5.535","article-title":"Alkaline phosphatase-positive malignant lymphoma. A subtype of B-cell lymphomas","volume":"68","author":"Nanba","year":"1977","journal-title":"Am. J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103038_bib1195","first-page":"1","article-title":"SOX11 is a biomarker for cyclin D1-negative mantle cell lymphoma","volume":"4","author":"Narurkar","year":"2016","journal-title":"Biomarker Res."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1200","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1158\/0008-5472.CAN-09-1095","article-title":"MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in mantle cell lymphomas","volume":"69","author":"Navarro","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1205","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biological and clinical features","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1210","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1158\/1078-0432.CCR-12-3077","article-title":"MicroRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics","volume":"19","author":"Navarro","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1215","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bjh.12854","article-title":"SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma \u2013 a nordic lymphoma group study","volume":"166","author":"Nordstrom","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1220","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O\u2019Connor","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1225","first-page":"1616","article-title":"PILLAR-1: preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to bortezomib","volume":"116","author":"O\u2019Connor","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1230","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/bjh.14141","article-title":"Efficacy of the GemOx-R regimen leads to the identification of oxaliplatin as a highly effective drug against mantle cell lymphoma","volume":"174","author":"Obrador-Hevia","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1235","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s002770050491","article-title":"Central nervous system involvement in patients with mantle cell lymphoma","volume":"78","author":"Oinonen","year":"1999","journal-title":"Ann Hematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1240","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","article-title":"A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, non nodal disease","volume":"101","author":"Orchard","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1245","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2559.1994.tb00533.x","article-title":"The anaplastic variant of centrocytic lymphoma is marked by frequent rearrangements of the bcl-1 gene and high proliferation indices","volume":"24","author":"Ott","year":"1994","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1250","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood-2014-04-569566","article-title":"SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma","volume":"124","author":"Palomero","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1255","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2015.355","article-title":"Sox 11 defines two different subtype of mantle cell lymphoma through transcriptional regulation of BCL6","volume":"30","author":"Palomero","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1260","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1265","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.V89.1.272","article-title":"Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas","volume":"89","author":"Pinyol","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1270","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1182\/blood-2006-11-057208","article-title":"Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis","volume":"109","author":"Pinyol","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1275","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.ajpath.2017.02.017","article-title":"Numerous ontogenic roads to mantle cell lymphoma","volume":"187","author":"Poliou","year":"2017","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1280","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1634\/theoncologist.2012-0425","article-title":"A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma","volume":"18","author":"Ponzoni","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1285","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.seminhematol.2011.05.002","article-title":"Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance","volume":"48","author":"Pott","year":"2011","journal-title":"Semin Hematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1290","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1295","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle celllymphoma after combined immunochemotherapy: a European MCLintergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1300","article-title":"MRD eradication should be the therapeutic goal in mantle cell lymphoma and may enable tailored treatment approaches: results of the intergroup trials of the European MCL network","author":"Pott","year":"2014","journal-title":"Blood. ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1305","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood.V90.2.894b","article-title":"Serum Ig abnormalities in mantle cell lymphoma","volume":"90","author":"Preud\u2019homme","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1310","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1182\/blood-2017-10-764373","article-title":"Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions","volume":"131","author":"Puente","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1315","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ccell.2016.09.014","article-title":"Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B cell lineage","volume":"30","author":"Quieros","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1320","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1182\/blood-2002-01-0263","article-title":"Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis","volume":"101","author":"Quintanilla-Martinez","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1325","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/leu.2011.305","article-title":"The miRNA-17 approximately 92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K\/AKT pathway activation","volume":"26","author":"Rao","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1330","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0959-8049(02)00456-2","article-title":"Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma","volume":"39","author":"Raty","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1335","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","article-title":"A multicenter II trial (SAKK 36\/06) of single agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma","volume":"97","author":"Renner","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1340","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/modpathol.2015.99","article-title":"Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the sox 11-negative subtype","volume":"28","author":"Ribera-Cortada","year":"2015","journal-title":"Mod Pathol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1345","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Riedberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1350","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00277-006-0193-2","article-title":"The hyper-CVAD-Rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma","volume":"86","author":"Ritchie","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1355","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1360","first-page":"457","article-title":"Identification of prognostic factors predicting the outcome of reduced intensity allogeneic stemcell transplantation in mantle cell lymphoma","volume":"112","author":"Robinson","year":"2008","journal-title":"An Analysis from the Lymphoma Working Party of the EBMT. ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1365","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2014.223","article-title":"The EBMT\/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma","volume":"29","author":"Robinson","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1370","first-page":"833","article-title":"Rituximab (R) + hyperCVAD alternating with R-Methotrexate\/Cytarabine after 9 years: continued high rate of failure-free survival in untreated mantle cell lymphoma(MCL)","volume":"112","author":"Romaguera","year":"2008","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1375","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cncr.11096","article-title":"Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma","volume":"97","author":"Romaguera","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1380","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1385","first-page":"3051","article-title":"Phase I trial of bortezomibin combination with rituximab-HYPER CVAD\/methotrexate and cytarabine for untreated mantle cell lymphoma","volume":"112","author":"Romaguera","year":"2008","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1390","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.ijrobp.2006.02.011","article-title":"Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT)","volume":"65","author":"Rosenbluth","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1395","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1400","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/leu.2012.72","article-title":"Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease","volume":"26","author":"Royo","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1405","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1410","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1415","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1420","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of akt contributes to the pathogenesis and survival of mantle celllymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1425","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3324\/haematol.2015.128710","article-title":"The addition of rituximab to fludarabine and cyclophosphamide chemotherapy resulted in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK national cancer research institute trial","volume":"101","author":"Rule","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1430","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0959-8049(02)00143-0","article-title":"Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin\u2019s lymphoma","volume":"38","author":"Rummel","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1435","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1440","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","article-title":"Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial","volume":"17","author":"Rummel","year":"2016","journal-title":"Lancet Oncol."},{"issue":"Abstract","key":"10.1016\/j.critrevonc.2020.103038_bib1445","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood.V112.11.2596.2596","article-title":"Bendamustine plus Rituximab versus CHOP plus Rituximab in the first-line treatment of patients with follicular, indolent and mantle cell lymphomas: Results of a randomized phase III study of the study group indolent lymphomas (StiL)","volume":"112","author":"Rummel","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1450","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0016-5085(97)70212-9","article-title":"Multiple lymphomatous polyposis of the gastrointestinal tract: prospective clinicopathologic study of 31 cases. Groupe D\u2019Etude des Lymphomes Digestifs","volume":"112","author":"Ruskone-Fourmestraux","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1455","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","article-title":"Pathogenic role of B-cell receptor signaling and canonical NF-kB activation in mantle cell lymphoma","volume":"128","author":"Saba","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1460","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1097\/01.pas.0000208899.15859.cb","article-title":"Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study","volume":"30","author":"Salar","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1465","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1200\/JCO.2006.08.4251","article-title":"Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature","volume":"25","author":"Salaverria","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1470","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2012-08-452284","article-title":"CCND2 rearrangements are the most frequent genetic events in cyclin D1- mantle cell lymphoma","volume":"121","author":"Salaverria","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1475","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ejca.2007.12.016","article-title":"Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States","volume":"44","author":"Sant","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1480","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0046-8177(03)00286-7","article-title":"Prominent intrasinusoidal infiltration of the bone marrow by mantle cell lymphoma","volume":"34","author":"Schenka","year":"2003","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1485","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle celllymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1490","first-page":"155","article-title":"Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature","volume":"6","author":"Setoodeh","year":"2013","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1495","first-page":"227","article-title":"Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches","volume":"19","author":"Shah","year":"2012","journal-title":"Cancer Contr."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103038_bib1500","first-page":"227","article-title":"Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches","volume":"19","author":"Shah","year":"2012","journal-title":"Cancer Contr."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1505","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.semcancer.2011.09.010","article-title":"Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes","volume":"21","author":"Smedby","year":"2011","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1510","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/jco.2006.24.18_suppl.7503","article-title":"Phase II study of rituximab+CHOP followed by 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1499)","volume":"24","author":"Smith","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1515","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2012.42.2444","article-title":"Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90\u2013Ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group study E1499","volume":"30","author":"Smith","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1520","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004\u20132014: sub-type analyses from the UK\u2019s haematological malignancy research network","volume":"112","author":"Smith","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1525","first-page":"2147","article-title":"Sustained graft-versus lymphoma effect among patients (pts) with mantle cell lymphoma (MCL) given nonmyeloablative allogeneic hematopoietic cell transplantation(HCT)","volume":"112","author":"Sorror","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1530","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3109\/10428194.2011.575489","article-title":"Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma","volume":"52","author":"Spurgeon","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1535","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMra020067","article-title":"Molecular diagnosis of the hematologic cancers","volume":"348","author":"Staudt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1540","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1182\/blood.V94.9.3262","article-title":"Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma","volume":"94","author":"Stilgenbauer","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1545","first-page":"181","article-title":"Centrocytic lymphoma:a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse","volume":"113","author":"Swerdlow","year":"1983","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1550","volume":"Volume 2","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1555","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M.D. Anderson cancer center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1560","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1565","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/onc.2013.177","article-title":"Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma","volume":"33","author":"Teshima","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1570","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/modpathol.3800237","article-title":"Mantle cell lymphomas with clonal immunoglobulin v(H)3-21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin v(H) genes","volume":"18","author":"Thelander","year":"2005","journal-title":"Mod Pathol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1575","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/cncr.21313","article-title":"Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma","volume":"104","author":"Thieblemont","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1580","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/10428190400029841","article-title":"Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP","volume":"46","author":"Thomas","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1585","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","article-title":"Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network","volume":"131","author":"Tiemann","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1590","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/bjh.13818","article-title":"Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601","volume":"172","author":"Till","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1595","first-page":"314","article-title":"Familial lymphoid neoplasms in patients with mantle cell lymphoma","volume":"89","author":"Tort","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1600","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator\u2019s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial","volume":"17","author":"Trneny","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1605","first-page":"859","article-title":"Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation","volume":"20","author":"Tsai","year":"1997","journal-title":"BoneMarrow Transplant"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1610","article-title":"Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement \u2013 a multi-centre case series from the United Kingdom","volume":"16","author":"Tucker","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1615","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/ajcp\/110.5.582","article-title":"Flowcytometric and immunohistochemical analysis of small lymphocytic lymphoma, mantle cell lymphoma, and plasmacytoid small lymphocytic lymphoma","volume":"110","author":"Tworek","year":"1998","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1620","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V88.4.1177.bloodjournal8841177","article-title":"Direct visualizationof dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization","volume":"88","author":"Vaandrager","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1625","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.2008.07498.x","article-title":"High-dose ara-C and beam with autograft rescue in R-CHOP responsive mantle celllymphoma patients","volume":"144","author":"van\u2019t Veer","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"121","key":"10.1016\/j.critrevonc.2020.103038_bib1630","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.29498","article-title":"Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"15","author":"Vaughn","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1635","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2012-06-438937","article-title":"SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma","volume":"121","author":"Vegliante","year":"2013","journal-title":"Blood"},{"issue":"48","key":"10.1016\/j.critrevonc.2020.103038_bib1640","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bcmd.2011.09.007","article-title":"The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines","volume":"15","author":"Visco","year":"2012","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1645","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell Non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1650","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood.V128.22.472.472","article-title":"Rituximab, bendamustine and cytarabine (RBAC 500) as induction therapy in elderly patients with mantle cell lymphoma: final results of a phase 2 study from the fondazione italiana linfomi","volume":"128","author":"Visco","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1655","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/modpathol.3880144","article-title":"Blastic mantle cell leukemia: an unusual presentation of blastic mantle cell lymphoma","volume":"13","author":"Viswanatha","year":"2000","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1660","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ajh.24094","article-title":"Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management","volume":"90","author":"Vose","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1665","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1200\/jco.2013.31.15_suppl.8501","article-title":"Preliminary results of PI3K{delta} inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine\/rituximab in patients with previously treated mantle cell lymphoma (MCL)","volume":"31","author":"Wagner-Johnston","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1670","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1586\/17474086.2014.889561","article-title":"Risk factors for etiology and prognosis of mantle cell lymphoma","volume":"7","author":"Wang","year":"2014","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1675","first-page":"764","article-title":"Racial differences in mantle cell lymphoma in the United States","volume":"14","author":"Wang","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1680","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1200\/JCO.2009.21.8545","article-title":"Phase II study of yttrium-90-ibritumomabtiuxetan in patients with relapsed or refractory mantle cell lymphoma","volume":"27","author":"Wang","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1685","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1182\/blood-2006-06-031948","article-title":"Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10211 cases and 11905 controls from the International lymphoma epidemiology consortium (InterLymph)","volume":"109","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1690","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1695","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1700","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/bjh.12780","article-title":"Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study","volume":"165","author":"Wang","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1705","article-title":"Efficacy and safety of single-agent ibrutinib in patients with mantle cell lymphoma who progressed after bortezomib therapy","volume":"124","author":"Wang","year":"2014","journal-title":"Blood. (ASH proceedings)"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1710","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1715","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1182\/blood.V128.22.1786.1786","article-title":"Effectiveness of lenalidomide in patients with mantle cell lymphoma who relapsed\/progressed after or were refractory\/intolerant to ibrutinib: the MCL-004 study","volume":"128","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1720","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1725","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single arm multicentre phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol."},{"issue":"S2","key":"10.1016\/j.critrevonc.2020.103038_bib1730","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/hon.2437_132","article-title":"Ibrutinib-rituximab followed by reduced chemo-immunotherapy consolidation in young, newly diagnosed mantle cell lymphoma patients: a window of opportunity to reduce chemotherapy","volume":"35","author":"Wang","year":"2017","journal-title":"Abstract) Hematol Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1735","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1200\/jco.2006.24.18_suppl.7533","article-title":"Efficacy of radioimmunotherapy with (90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: results of two phase II trials of the European MCL network and the PLRG","volume":"24","author":"Weigert","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1740","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/1097-0142(19820401)49:7<1429::AID-CNCR2820490720>3.0.CO;2-5","article-title":"Mantle-zone lymphoma: a follicular variant of intermediate lymphocytic lymphoma","volume":"49","author":"Weisenburger","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1745","first-page":"1629","article-title":"Templated nucleotide addition and immunoglobulin JH-gene utilization in t (11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma","volume":"61","author":"Welzel","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1750","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1182\/blood-2006-08-039859","article-title":"Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival","volume":"109","author":"Wiestner","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1755","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bbmt.2014.01.004","article-title":"Phase I\/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent Non-Hodgkin lymphoma, transformed, or mantle cell lymphoma","volume":"20","author":"William","year":"2014","journal-title":"Biol. Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1760","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1765","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1182\/blood-2007-10-118794","article-title":"Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas","volume":"111","author":"Wlodarska","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1770","doi-asserted-by":"crossref","first-page":"42362","DOI":"10.18632\/oncotarget.5705","article-title":"High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival","volume":"6","author":"Yi","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1775","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1080\/10428190127511","article-title":"Efficacy of splenectomy for patients with mantle cell non-Hodgkin\u2019s lymphoma","volume":"42","author":"Yoong","year":"2001","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1780","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3324\/haematol.2011.051813","article-title":"Salvage treatment with lenalidomide and dexamethasone in relapsed\/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers","volume":"27","author":"Zaja","year":"2012","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2020.103038_bib1785","article-title":"Rituximab, lenalidomide, bendamustine second line therapy in mantle cell lymphoma: a phase II study of the Fondazione Italiana Linformi (FIL)","volume":"33","author":"Zaja","year":"2015","journal-title":"Hematol. Oncol. (ICML abstracts)"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1790","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1200\/jco.2006.24.18_suppl.7560","article-title":"Sequential radioimmunotherapy with tositumomab\/Iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions","volume":"24","author":"Zelenetz","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1795","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.6004\/jnccn.2014.0125","article-title":"Non-Hodgkin\u2019s lymphomas, version 4.2014: clinical practice guidelines in oncology","volume":"12","author":"Zelenetz","year":"2014","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1800","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood-2009-09-243147","article-title":"microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma","volume":"115","author":"Zhao","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103038_bib1805","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1365-2141.1996.5421085.x","article-title":"Large\u2010cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome","volume":"93","author":"Zoldan","year":"1996","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.103038_bib1810","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/oxfordjournals.annonc.a058904","article-title":"European lymphoma task force (ELTF): report of the workshop on mantle cell lymphoma (MCL)","volume":"5","author":"Zucca","year":"1994","journal-title":"Ann. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818302725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818302725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:39:19Z","timestamp":1760902759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842818302725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":362,"alternative-id":["S1040842818302725"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103038","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mantle cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103038"}}